Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $79.8571.

Several brokerages recently issued reports on TARS. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Wednesday, October 8th. Zacks Research raised Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Guggenheim upped their price objective on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. HC Wainwright raised their target price on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a research report on Monday, October 20th. Finally, Mizuho assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They set an “outperform” rating and a $100.00 price target for the company.

Insider Transactions at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total transaction of $332,220.00. Following the sale, the chief executive officer owned 812,106 shares of the company’s stock, valued at approximately $44,966,309.22. This represents a 0.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 8.97% of the stock is owned by insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its position in Tarsus Pharmaceuticals by 26.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after purchasing an additional 339 shares during the last quarter. Osaic Holdings Inc. raised its holdings in Tarsus Pharmaceuticals by 779.1% during the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after buying an additional 2,462 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Tarsus Pharmaceuticals by 220.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after buying an additional 2,782 shares during the period. Quarry LP boosted its position in Tarsus Pharmaceuticals by 20.0% during the 1st quarter. Quarry LP now owns 3,599 shares of the company’s stock valued at $185,000 after buying an additional 599 shares during the period. Finally, AlphaQuest LLC bought a new stake in Tarsus Pharmaceuticals in the 1st quarter worth $189,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $82.23 on Tuesday. The firm’s fifty day moving average is $72.49 and its 200-day moving average is $55.95. Tarsus Pharmaceuticals has a 52 week low of $38.51 and a 52 week high of $83.78. The firm has a market cap of $3.49 billion, a PE ratio of -40.71 and a beta of 0.74. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.25 and a current ratio of 4.29.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. The firm had revenue of $118.70 million during the quarter, compared to analyst estimates of $114.22 million. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. Sell-side analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.